

Barcelona, 12th October 2023

OTHER RELEVANT INFORMATION

Almirall and EpimAb Biotherapeutics Announce Bispecific Antibody License Agreement

In accordance with Securities Markets Law, Almirall S.A. (“Almirall”) announces the following:

Almirall and EpimAb Biotherapeutics today announced a license agreement on the development of bispecific antibodies for up to three undisclosed target pairs. Under the terms of this agreement, Almirall will gain a license to utilize EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig[®]) platform technology to generate, develop and commercialize bispecific antibodies, for which Almirall will have exclusive global rights. EpimAb Biotherapeutics shall retain all rights to the FIT-Ig[®] Technology.

Within the terms of the agreement, Almirall will assume full cost and responsibility for the global development and commercialization of the bispecific antibodies. EpimAb Biotherapeutics will receive milestone payments, contingent upon launch and commercial success of multiple products, plus royalties on net sales for any commercialized product.

FIT-Ig[®], EpimAb’s proprietary technology platform, generates bispecific antibodies solely utilizing the basic structural parts of monoclonal antibodies without adding any complex changes, and is patented in all major markets of the world. With four bispecific molecules advanced into the clinic using this technology, EpimAb has also demonstrated the potential of this novel platform to rapidly advance drug candidates from idea to development.

Sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com